Leiomyoma

Oncology·MeSH: Leiomyoma

Prevalence

0.1 / 100K

7 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
sodium	Amneal Pharmaceuticals, Inc. (AMRX)
sodium nitroprusside	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(2)

Drug	Company
Cetuximab Sarotalocan Sodium	Amneal Pharmaceuticals, Inc. (AMRX)
Erlotinib	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 2(3)

Drug	Company
Erlotinib	ADMA BIOLOGICS, INC. (ADMA)
Sodium Fluoride F-18	ADMA BIOLOGICS, INC. (ADMA)
Sodium Fluoride F-18	Amneal Pharmaceuticals, Inc. (AMRX)

BioSniper tracks 7 drugs in development for Leiomyoma across 2 companies.

There are 3 clinical trials targeting Leiomyoma tracked by BioSniper.

The estimated prevalence of Leiomyoma is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.